What's new in Interventional Cardiology

View a snapshot of the results of these 3 trials presented in London: TRISCEND II, COMPARE-TAVI cohort B and the 30-day Outcomes of the TF J-VALVE for Chronic AR

Drug-coated balloon (DCB) angioplasty has become a valuable alternative to drug-eluting stents in treating coronary artery disease. To achieve optimal outcomes, proper lesion preparation and techniques to minimise drug loss are crucial.

This article highlights key steps and best practices for performing DCB angioplasty, ensuring effective drug delivery and...

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.

Julia Grapsa provides her take on the Chronic Coronary Syndromes (CCS) Guidelines which were presented by Felicita Andreotti and Christiaan Vrints at ESC Congress 2024 in London.

In coronary bifurcation lesions (CBL) PCI, intracoronary imaging (ICI) is preferred for its superior outcomes over angiography alone, but its adoption is limited by education and technology access barriers, resulting in most CBL PCIs still using angiographic guidance only.

Davide Capodanno presents notable trial updates, coronary devices, and key takeaways from EuroPCR 2024. Highlights include the SOLVE-TAVI and IDEAL-LM trials at 5 years, BIOADAPTOR at 2 years, advancements in drug-coated balloons and DES, as well as insights from REC-CAGEFREE II, LANDMARK, and NOTION-2.

References

• SOLVE-TAVI: Feistritzer HJ, et al....

In this video, Thomas Cuisset and Davide Capodanno discuss with Dejan Milasinovic key moments in coronary intervention at EuroPCR 2024. They highlight innovations in intravascular imaging education, featuring the Imaging Learning Center and its hands-on workstations, and key studies like DOCTOR-LM, following in the footsteps of OCTOBER or BIFURCATION. Educating...

Jonathan Curio provides his take on the PROTECTED TAVR study which was presented by Samir R. Kapadia at TCT 2022. The aim was to evaluate whether TAVR with cerebral embolic protection would reduce the rate of clinical stroke in transfemoral TAVR.

The authors investigated whether iatrogenic atrial septal defect closure post-transcatheter mitral valve edge-to-edge repair is superior to conservative therapy, and whether outcomes (death/heart failure hospitalization) differ between patients with and without an iASD post-TMVR.